Abstract:Objective To explore changes of metabolites in APP/ PS1 double transgenie mice of Alzbeimer disease (AD) by 1H-MR spectroscopy (1H-MRS) and the application value of in early diagnosis of AD.Methods 1H-MRS was performed in 35 APP/PS1 transgenie mice of AD ( study group) and 20 wild type mice ( control group) at age of 3, 6 and 9 months using a 7.0 T MR system.Sub-peak areas of N-acetyl aspartate (NAA), myo-inositol (mI) and creatine (Cr) in the cerebral cortex and hippocampus were measured, and the NAA/Cr and mI/Cr ratios were calculated.The changes in pathology between the two groups were compared.Using the lower limit of 95% confidence interval (CI) of the ml/Cr ratio and the upper limit of 95% CI of the NAA/Cr ratio of AD mice as the threshold, their influences on sensitivity,specificity and accuracy of various age groups of AD animals were compared.Comparison of the 1H-MRS indexes between study mice and wild type mice at each time point were conducted by a two-sample t test.Results The mean mI/Cr ratios of AD mice were 0.68± 0.03, 0.72± 0.04, and 0.77 ± 0.04 respectively at 3, 6 and 9 months of age; while they were 0.63 ± 0.04, 0.64 ± 0.03, and 0.64 ± 0.04 respoetively in control group, the difference was significant ( t = 2.814, 5.146, 14.437, P < 0.01 ).Compared with the control group, the mI/Cr ratio of the 3-month-old AD mice of the study group was significantly increased,and histological examination showed proliferation and activation of neuroglial cells in the cerebral cortex and hippoeampus.The mean NAA/Cr ratio were 1.17 ±0.08, 1.04 ±0.05, and 0.90 ±0.05 respectively at 3,6 and 9 months of age in study group, while they were 1.18 ±0.07, 1.16 ±0.07, and 1.18 ±0.08respectively in control group.There were no significant difference ( t = 0.752, P > 0.05 ) between the study group and control group at 3 months of age, and the NAA/Cr ratio decreased significantly only at 6 and 9 months of age ( t = - 8.514, - 5.646, P < 0.01 ).The immunohistochemical exam demonstrated the appearance of Aβ plaque.According to threshold of mI/Cr, the sensitivity of AD mice of 3, 6 and 9 months of age was 80% (28/35), 84% ( 26/31 ) and 85% ( 23/27 ), and the specificity was 85% ( 17/20 ),94% (17/18) and 100% ( 16/16), and the accuracy was 82% (45/55), 88% (43/49) and 91% (39/43),respectively.For NAA/Cr, the sensitivity of AD mice of 6 and 9 months of age was 84% (26/31) and 89% (24/27), and the specificity was 89% (16/18) and 100% (16/16), and the accuracy was 86% (42/49) and 93% (40/43), respectively.Conclusions NAA and mI are the most sensitive and specific markers for early assessment of AD, and change of mI is earlier than that of NAA.Quantitative analysis of mI may provide important clues for early diagnosis of AD.

Magnetic Resonance Spectroscopy in Alzheimer’s Disease: Systematic Review and Meta-Analysis

Meta-Analysis of Neurochemical Changes Estimated via Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Alzheimer's Disease

Study of Regional Metabolites by Quantitative Proton MR Spectroscopy in APP/PS1 Double Transgenic Alzheimer Disease Mice

Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.

Magnetic resonance spectroscopy for mild cognitive impairment and Alzheimer's disease

Proton Magnetic Resonance Spectroscopy Detects A Relative Decrease of N-Acetylaspartate in the Hippocampus of Patients with Dementia with Lewy Bodies

Using Proton Magnetic Resonance Spectroscopy to Identify Mild Cognitive Impairment.

1H-MRS Changes in Mild Cognitive Impairment and Alzheimer's Disease

Study on biochemical metabolism of brain tissues by proton magnetic resonance spectroscopy in Alzheimer patients

Early Alzheimer's disease neuropathology detected by proton MR spectroscopy.

Brain Proton Magnetic Resonance Spectroscopy in Mild Cognitive Impairment and Mild Alzheimer Disease

Role of Myo-Inositol by Magnetic Resonance Spectroscopy in Early Diagnosis of Alzheimer'S Disease in App/Ps1 Transgenic Mice

Retracted: 1h-Mrs Can Monitor Metabolites Changes Of Lateral Intraventricular Bdnf Infusion Into A Mouse Model Of Alzheimer'S Disease In Vivo(Retracted Article. See Vol. 254, Pg. 477, 2013)

Understanding Proton Magnetic Resonance Spectroscopy Neurochemical Changes Using Alzheimer's Disease Biofluid, PET, Postmortem Pathology Biomarkers, and APOE Genotype

Applications of magnetic resonance spectroscopy in diagnosis of neurodegenerative diseases: A systematic review

Neurometabolic Characteristics in the Anterior Cingulate Gyrus of Alzheimer’s Disease Patients with Depression: a 1H Magnetic Resonance Spectroscopy Study

1H-MRS can monitor metabolites changes of lateral intraventricular BDNF infusion into a mouse model of Alzheimer's disease in vivo.

Magnetic resonance spectroscopy in evaluating hippocampus changes of patients with mild cognitive impairment

Metabolic Changes in Patients with Alzheimer's Disease Assessed by High Field Proton Magnetic Resonance Spectroscopy

Quantitative multivoxel proton MR spectroscopy study of brain metabolites in patients with amnestic mild cognitive impairment: a pilot study

Retracted: 1H-MRS Can Monitor Metabolites Changes of Lateral Intraventricular BDNF Infusion into a Mouse Model of Alzheimer’s Disease in Vivo [neuroscience 245 (2013) 40–49]